Table 2 Primary outcome (cytokine clearance of hemofilter adsorption)
Mediators | Clearance | Sampling time window | AN69ST | PMMA | P valuea |
|---|---|---|---|---|---|
(n = 26) | (n = 26) | ||||
HMGB1 | Plasma clearance (mL/min) | 2–6 h | 43.6 (30.2–52.8) | 5.1 (− 15.5–17.5) |  < 0.001 |
12–24 h | 20.1 (6.7–45.2) | 0.9 (− 20.0–11.1) |  < 0.001 | ||
Transmembrane clearance (mL/min) | 2–6 h | 0 (0–0) | 0 (0–0.34) | 0.16 | |
12–24 h | 0 (0–0.35) | 0 (0–0.18) | 0.47 | ||
Clearance of hemofilter adsorption (mL/min) | 2–6 h | 43.6 (29.8–52.8) | 3.6 (-15.9–17.5) |  < 0.001 | |
12–24 h | 20.1 (6.2–45.2) | − 0.7 (− 20.0–11.1) |  < 0.001 | ||
TNF-α | Plasma clearance (mL/min) | 2–6 h | 33.5 (28.8–36.3) | 26.2 (7.5–30.0) |  < 0.01 |
12–24 h | 24.7 (18.6–32.3) | 13.8 (9.2–24.1) |  < 0.01 | ||
Transmembrane clearance (mL/min) | 2–6 h | 0.01 (0–0.07) | 0 (0–0.06) | 0.70 | |
12–24 h | 0.04 (0–0.09) | 0 (0–0.02) |  < 0.05 | ||
Clearance of hemofilter adsorption (mL/min) | 2–6 h | 33.5 (29.4–36.8) | 26.4 (6.9–30.2) |  < 0.01 | |
12–24 h | 25.0 (20.4–32.2) | 14.0 (9.1–24.9) |  < 0.01 | ||
IL-6 | Plasma clearance (mL/min) | 2–6 h | 9.4 (7.8–12.1) | 17.6 (10.7–22.5) |  < 0.001 |
12–24 h | 9.2 (5.6–12.0) | 9.1 (4.0–14.7) | 0.82 | ||
Transmembrane clearance (mL/min) | 2–6 h | 1.8 (1.6–2.2) | 0 (0–0.01) |  < 0.001 | |
12–24 h | 1.72 (1.26–2.12) | 0.08 (0–0.22) |  < 0.01 | ||
Clearance of hemofilter adsorption (mL/min) | 2–6 h | 7.6 (4.3–10.6) | 17.6 (10.7–22.4) |  < 0.001 | |
12–24 h | 7.4 (3.4–9.8) | 9.1 (3.7–14.6) | 0.29 | ||
IL-8 | Plasma clearance (mL/min) | 2–6 h | 47.4 (33.0–50.5) | 6.2 (− 8.7–12.0) |  < 0.01 |
12–24 h | 33.9 (14.9–46.4) | 3.4 (− 31.0–9.3) |  < 0.01 | ||
Transmembrane clearance (mL/min) | 2–6 h | 0.15 (0.04–0.87) | 1.34 (1.04–4.89) |  < 0.01 | |
12–24 h | 0.4 (0.2–1.2) | 3.9 (3.1–11.2) |  < 0.01 | ||
Clearance of hemofilter adsorption (mL/min) | 2–6 h | 47.0 (31.8–50.7) | 4.5 (-11.4–10.6) |  < 0.001 | |
12–24 h | 34.1 (13.6–44.6) | 0.7 (− 50.0–5.8) |  < 0.001 | ||
IL-10 | Plasma clearance (mL/min) | 2–6 h | 28.3 (23.1–36.6) | 27.2 (16.5–30.3) | 0.37 |
12–24 h | 26.0 (18.1–29.1) | 18.8 (12.9–24.8) | 0.07 | ||
Transmembrane clearance (mL/min) | 2–6 h | 0 (0–0.01) | 0 (0–0) | 0.18 | |
12–24 h | 0.02 (0.01–0.06) | 0.01 (0–0.01) |  < 0.01 | ||
Clearance of hemofilter adsorption (mL/min) | 2–6 h | 28.3 (23.1–35.6) | 27.2 (16.5–30.3) | 0.36 | |
12–24 h | 26.0 (17.7–29.0) | 18.7 (12.9–24.8) | 0.07 | ||
IL-18 | Plasma clearance (mL/min) | 2–6 h | − 0.4 (-3.3–2.3) | − 0.6 (− 3.0–1.5) | 0.73 |
12–24 h | − 0.2 (-3.1–2.4) | − 2.5 (− 4.7–0.7) | 0.17 | ||
Transmembrane clearance (mL/min) | 2–6 h | 0.01 (0–0.01) | 0.10 (0.06–0.13) |  < 0.001 | |
12–24 h | 0.01 (0–0.01) | 0.01 (0.04–0.01) |  < 0.001 | ||
Clearance of hemofilter adsorption (mL/min) | 2–6 h | − 0.4 (-3.3–2.3) | − 0.7 (− 3.2–1.4) | 0.62 | |
12–24 h | − 0.6 (− 2.4–2.5) | − 2.5 (− 4.7–0.6) | 0.09 | ||
MIG | Plasma clearance (mL/min) | 2–6 h | 64.9 (61.9–66.9) | 24.0 (18.8–32.9) |  < 0.001 |
12–24 h | 59.3 (52.4–61.8) | 10.7 (7.4–19.2) |  < 0.001 | ||
Transmembrane clearance (mL/min) | 2–6 h | 0.13 (0.06–0.20) | 0.19 (0.05–0.76) | 0.30 | |
12–24 h | 0.48 (0.18–0.86) | 2.00 (0.66–2.33) |  < 0.05 | ||
Clearance of hemofilter adsorption (mL/min) | 2–6 h | 64.6 (61.6–66.7) | 24.0 (18.0–32.2) |  < 0.001 | |
12–24 h | 58.6 (49.2–61.2) | 8.3 (5.2–17.6) |  < 0.001 | ||
MIP-1α | Plasma clearance (mL/min) | 2–6 h | 64.3 (60.9–65.9) | 38.9 (16.1–45.7) |  < 0.001 |
12–24 h | 54.9 (48.1–58.9) | 20.9 (5.0–31.7) |  < 0.001 | ||
Transmembrane clearance (mL/min) | 2–6 h | 0.02 (0.01–0.05) | 0.01 (0–0.02) |  < 0.05 | |
12–24 h | 0.22 (0.04–0.67) | 0.14 (0.01–0.61) | 0.36 | ||
Clearance of hemofilter adsorption (mL/min) | 2–6 h | 64.2 (60.9–65.9) | 38.9 (16.0–45.8) |  < 0.001 | |
12–24 h | 54.8 (47.4–58.9) | 20.6 (4.3–31.6) |  < 0.001 |